IGSF9 and bladder transitional cell carcinoma: On the other hand, IGSF9 shows high expression in bladder urothelial carcinoma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, uterine corpus endometrial carcinoma [38].